SBIR/STTR Research Award
Long acting injected liposomal buprenorphine for chronic pain/addiction in people
Award amount
$206,718Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PLUMB PHARMACEUTICALS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HB4LN3AQR226
- Solicitation number
- DA14-013
- Topic code
- NIDA
Research abstract
DESCRIPTION: In this proposal, Comfort Care for Animals LLC (CCA) (Madison, WI) will create slow-release (minimum 10-12 days in this Phase, with an ultimate goal of 28 days) injectable liposomal buprenorphine formulation to treat moderate to severe post-surgical or chronic pain in people and animals and to use as a treatment for opioid addiction in people. This innovative new drug-delivery system aims to address the widespread problem of providing long-term, non-divertible opioid pain relief for moderate to severe pain while also eliminating troughs in analgesia. We selected buprenorphine for this application because it is widely used as a maintenance therapy for opioid addiction, and as a treatment for surgical and chronic pain, but our novel delivery system should work with a large variety of additional drugs. This delivery system could provide reliable, long-duration analgesia or withdrawal symptom suppression from a single, monthly injection administered by trained medical professionals, removing a
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A 3-month Release Naltrexone for Addiction Treatment
- SBIR Phase I: Refining a 3-month release buprenorphine, advancing a drug delivery platform
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
3 SBIR/STTR records share this UEI (2014–2018). Reported award amounts total $709,317. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services, National Science Foundation